Growth Hormone Peptides: Sermorelin, Ipamorelin, and CJC-1295 Explained (2026)

Growth hormone has the most paradoxical relationship with longevity of any molecule in human biology. In the anti-aging clinic world, it is positioned as a fountain of youth – restoring muscle mass, burning fat, improving sleep, and reversing the visible signs of aging. In the longevity research world, it is positioned as a pro-aging signal – one of the most consistent life-shortening pathways across every organism studied from yeast to humans.

Both positions are supported by data. Both communities cite real evidence. And the tension between them remains one of the most important unresolved questions in the science of aging.

Growth hormone secretagogues – peptides like Sermorelin, Ipamorelin, and CJC-1295 that stimulate your pituitary gland to release its own growth hormone – sit directly in the middle of this paradox. They are among the most prescribed peptides in anti-aging medicine. They are also, from a mechanistic standpoint, activating one of the pathways that longevity research has consistently identified as life-shortening.

This article explains what these peptides are, how they work, what the evidence shows, and why the GH-longevity paradox is more nuanced than either side typically acknowledges.

TL;DR -- Key Takeaways

• GH secretagogues (Sermorelin, Ipamorelin, CJC-1295) stimulate your pituitary gland to release its own growth hormone, rather than injecting exogenous GH directly
• GH production declines approximately 14% per decade after age 30 -- a process called somatopause
• Sermorelin: GHRH analog, FDA-approved for GH deficiency diagnosis in children, used off-label in adults. Mimics the natural signal from the hypothalamus
• Ipamorelin: selective growth hormone releasing peptide (GHRP), mimics ghrelin without cortisol or prolactin elevation. Often considered the "cleanest" GH peptide
• CJC-1295: modified GHRH with extended half-life (days vs minutes), often combined with Ipamorelin for sustained GH elevation
• Benefits in research: improved body composition, sleep quality, skin elasticity, injury recovery, bone density
• The GH-longevity paradox: GH/IGF-1 pathway is consistently PRO-AGING in longevity research -- Laron dwarfs live longer, GH receptor knockouts live 40% longer in mice
• The nuance: pulsatile GH release (from peptides) may differ physiologically from chronically elevated GH, and context (age, health status, dosing) may determine whether GH signaling helps or harms
• Safety concerns: potential cancer risk with chronically elevated IGF-1, theoretical conflict with longevity goals

Quick Facts: GH Secretagogues (Ipamorelin + CJC-1295)

• Dose: Ipamorelin 200-300mcg + CJC-1295 100mcg subcutaneous injection
• Form: Reconstituted peptide (injection)
• Timing: Before bed (aligns with natural GH pulse)
• Evidence: Moderate (individual peptide studies; limited combination RCTs)
• Who it's for: Adults with documented GH decline, under physician supervision -- not a first-line longevity intervention

Growth Hormone: The Basics

Growth hormone (GH, also called somatotropin) is a 191-amino-acid protein produced by somatotroph cells in the anterior pituitary gland (a pea-sized organ at the base of the brain that acts as the master endocrine controller). GH is released in pulses – the largest occurring during deep slow-wave sleep – not in a steady stream.

GH acts through two primary pathways:

1. Direct effects – GH binds to GH receptors on target tissues (muscle, bone, fat), directly stimulating cell growth, protein synthesis, and fat mobilization.
2. IGF-1 mediation – GH stimulates the liver to produce IGF-1 (insulin-like growth factor 1 – a hormone structurally similar to insulin that mediates many of growth hormone's effects on tissue growth and metabolism). IGF-1 then acts on tissues throughout the body to promote cell growth, division, and survival.

The GH → IGF-1 axis is one of the most powerful anabolic (tissue-building) signaling cascades in human biology. During childhood and adolescence, it drives linear growth, muscle development, and organ maturation. In adults, it maintains muscle mass, bone density, fat metabolism, and tissue repair.

The Somatopause: GH Decline With Age

GH production declines approximately 14% per decade after age 30. By age 60, most adults produce less than half the GH they produced at 25. This age-related decline is called somatopause (analogous to menopause for estrogen or andropause for testosterone).

The consequences of declining GH are well-documented:

• Decreased muscle mass (sarcopenia) – approximately 3-8% per decade after 30
• Increased visceral fat – particularly abdominal fat
• Reduced bone density – contributing to osteoporosis risk
• Thinner, less elastic skin – loss of collagen and dermal thickness
• Reduced exercise capacity – decreased VO2 max and recovery speed
• Impaired sleep quality – GH and deep sleep are bidirectionally linked
• Reduced immune function – GH supports thymic function and immune cell production

The question that launched the anti-aging GH industry: if restoring GH levels could reverse these changes, would it effectively reverse aspects of aging?

The Rudman Study: Where It All Started

In 1990, Daniel Rudman published a landmark paper in the New England Journal of Medicine (Rudman et al., 1990, PMID 2355952) that ignited the anti-aging GH movement. The study gave recombinant human growth hormone (rhGH) to 12 men aged 61-81 for six months.

Results:

• Lean body mass increased by 8.8%
• Adipose tissue mass decreased by 14.4%
• Skin thickness increased by 7.1%
• Lumbar vertebral bone density increased by 1.6%

The NEJM paper was cautious in its conclusions. The media was not. Headlines proclaimed that growth hormone reversed 10-20 years of aging. Anti-aging clinics began prescribing rhGH, and a multi-billion-dollar industry was born.

What Rudman's study did not show: any improvement in functional outcomes (strength, exercise capacity, cognitive function) or any effect on mortality. And subsequent research would reveal significant side effects of exogenous GH administration – joint pain, carpal tunnel syndrome, insulin resistance, edema, and potential cancer risk from chronically elevated IGF-1.

GH Secretagogues: The Peptide Alternative

GH secretagogues emerged as a potentially safer alternative to direct GH injection. The key distinction: instead of injecting growth hormone directly (which produces unphysiologically constant GH levels), secretagogues stimulate the pituitary to release GH in pulses – mimicking the body's natural rhythm.

There are two categories:

GHRH analogs – peptides that mimic growth hormone-releasing hormone (GHRH), the hypothalamic signal that tells the pituitary to release GH. Sermorelin and CJC-1295 fall in this category.

GHRPs (Growth Hormone Releasing Peptides) – peptides that mimic ghrelin (the "hunger hormone" produced by the stomach that also powerfully stimulates GH release from the pituitary). Ipamorelin falls in this category.

The combination of a GHRH analog + a GHRP produces synergistic GH release – greater than either peptide alone. This is why CJC-1295 + Ipamorelin is the most commonly prescribed GH peptide combination.

At a glance: GH peptides compared:

Sermorelin: The GHRH Analog

What It Is

Sermorelin (also known as GHRH 1-29) is a synthetic peptide consisting of the first 29 amino acids of the 44-amino-acid natural GHRH molecule. It retains the full biological activity of GHRH – meaning it binds to GHRH receptors on the pituitary gland and stimulates GH release just as the body's own GHRH does.

Sermorelin is the only GH secretagogue that has been FDA-approved – specifically for diagnostic testing and treatment of GH deficiency in children. It is used off-label in adults for age-related GH decline.

How It Works

1. Sermorelin binds to GHRH receptors on pituitary somatotrophs
2. This triggers GH release in a pulse (not a constant elevation)
3. The released GH acts on target tissues and stimulates liver IGF-1 production
4. The body's natural feedback mechanisms (somatostatin – the "GH brake" peptide from the hypothalamus) remain intact, preventing excessive GH elevation

This last point is clinically important: because Sermorelin works through the body's natural signaling cascade, the pituitary's self-regulatory mechanisms remain functional. If GH levels rise too high, somatostatin release increases and dampens further GH secretion. This built-in brake is absent when GH is injected directly.

Evidence

Walker (2006, Clinical Interventions in Aging) reviewed how Sermorelin increased GH pulse amplitude and IGF-1 levels in adults with age-related GH decline. Body composition improvements (reduced fat, increased lean mass) were observed over 12-week treatment periods.

Vittone et al. (1997, Journals of Gerontology) demonstrated that Sermorelin improved GH secretion patterns in healthy elderly men, partially restoring the sleep-associated GH pulse that declines with aging.

Sleep quality improvement is one of the most consistently reported effects of Sermorelin in clinical practice. GH secretion and slow-wave sleep are bidirectionally linked – GH is released during deep sleep, and GH signaling promotes deeper sleep. Sermorelin's restoration of GH pulses often improves sleep architecture as a secondary effect. For more on the sleep-aging connection, see Sleep and Longevity: What Supplements Actually Help.

Limitations

Sermorelin has a very short half-life – approximately 10-20 minutes. This means the GH pulse it triggers is brief, requiring daily injections (typically before bedtime to coincide with natural sleep-time GH release). This short duration of action led to the development of longer-acting alternatives.

Ipamorelin: The Selective GHRP

What It Is

Ipamorelin is a synthetic pentapeptide (five amino acids) that mimics ghrelin's GH-releasing action on the pituitary. It was developed in the 1990s specifically to stimulate GH release without the side effects associated with other GHRPs.

What Makes It "Selective"

Earlier GHRPs (GHRP-6, GHRP-2, hexarelin) stimulated GH release but also elevated cortisol (the stress hormone) and prolactin (a hormone associated with lactation and immune modulation). Elevated cortisol opposes many of GH's beneficial effects – increasing fat storage, suppressing immune function, and promoting muscle breakdown.

Raun et al. (1998, European Journal of Endocrinology) demonstrated that Ipamorelin stimulates GH release with a potency comparable to GHRP-6 but with minimal effect on cortisol, prolactin, or ACTH (adrenocorticotropic hormone – the pituitary hormone that stimulates cortisol production). This selectivity makes Ipamorelin the "cleanest" GHRP – it produces GH elevation without the hormonal side effects that complicate other GH peptides.

Mechanism

Ipamorelin binds to the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. This activates a signaling cascade independent of the GHRH receptor pathway – which is why combining Ipamorelin (GHRP pathway) with a GHRH analog (GHRH pathway) produces synergistic GH release.

Evidence

Raun et al. (1998) established Ipamorelin's GH-releasing potency and selectivity profile in rat and human studies. GH release was dose-dependent, with peak levels occurring 15-30 minutes after administration.

Anderson et al. (2001) demonstrated in post-surgical patients that Ipamorelin improved nitrogen balance (a marker of protein synthesis and tissue repair) and accelerated recovery without the cortisol elevation seen with GHRP-2.

The clinical evidence base for Ipamorelin is smaller than for Sermorelin, primarily because Ipamorelin has not been FDA-approved for any indication. Most clinical experience comes from off-label use in anti-aging medicine.

CJC-1295: The Long-Acting GHRH Analog

What It Is

CJC-1295 is a modified GHRH analog with a significantly extended half-life. Where Sermorelin lasts approximately 10-20 minutes, CJC-1295 with DAC (Drug Affinity Complex – a chemical modification that allows the peptide to bind to albumin in the blood, dramatically slowing its clearance) has a half-life of approximately 6-8 days.

Two Versions

CJC-1295 with DAC – the original version, which binds to blood albumin and provides sustained GH elevation over days. This produces a more continuous GH stimulation rather than sharp pulses.

CJC-1295 without DAC (also called Modified GRF 1-29 or MOD-GRF) – a version without the albumin-binding modification, with a half-life of approximately 30 minutes. This produces GH pulses rather than sustained elevation and is more commonly used in current practice because pulsatile GH release is considered more physiological.

The Ipamorelin + CJC-1295 Combination

The most commonly prescribed GH peptide protocol in anti-aging medicine combines CJC-1295 (without DAC) with Ipamorelin. The rationale:

• CJC-1295 (GHRH pathway) provides the base signal to the pituitary
• Ipamorelin (ghrelin pathway) amplifies the signal through an independent receptor
• Synergistic GH release – the two pathways together produce 2-3x more GH than either peptide alone
• Clean hormonal profile – no cortisol or prolactin elevation (from Ipamorelin's selectivity)
• Pulsatile release – when using CJC-1295 without DAC, the result is amplified GH pulses rather than chronic elevation

Evidence for the Combination

Teichman et al. (2006, JCEM) showed that CJC-1295 with DAC increased mean GH levels by 2-10 fold and IGF-1 levels by 1.5-3 fold, with effects lasting 6-14 days after a single injection. No serious adverse events were reported.

Clinical practice data – the CJC-1295/Ipamorelin combination is the most widely used GH peptide protocol in U.S. anti-aging medicine. Consistent reported outcomes include improved sleep quality, body composition changes (reduced fat, maintained or increased lean mass), improved skin quality, and subjective improvements in energy and recovery. However, rigorous placebo-controlled data for the combination is limited.

Benefits Reported in Research and Clinical Practice

The following benefits have been documented in GH secretagogue research and/or consistent clinical experience. They vary in evidence quality from strong (RCT-supported) to moderate (observational) to preliminary (clinical reports without controlled data).

Body Composition (Moderate-to-Strong Evidence)

GH secretagogues consistently reduce visceral fat and maintain lean mass. The effect on muscle mass is modest without concurrent resistance training – GH facilitates protein synthesis but does not build muscle in the absence of mechanical stimulus.

Sleep Quality (Moderate Evidence)

One of the most consistently reported benefits. GH secretagogues restore the GH-associated deep sleep pulse, improving sleep architecture. Patients frequently report deeper sleep and more vivid dreams within the first 1-2 weeks of use.

Skin Quality (Moderate Evidence)

GH stimulates collagen synthesis and dermal fibroblast proliferation. Clinical reports consistently describe improved skin thickness, elasticity, and hydration after 3-6 months of GH secretagogue use.

Recovery and Healing (Preliminary Evidence)

Accelerated recovery from exercise and injury is commonly reported. The mechanism is plausible – GH stimulates protein synthesis, collagen production, and IGF-1-mediated tissue repair. Controlled data specifically for GH secretagogues (vs. exogenous GH) is limited. For the broader picture on exercise and aging, see Exercise and Longevity: What Actually Works.

Bone Density (Moderate Evidence)

GH stimulates both osteoblast (bone-building cell) and osteoclast (bone-resorbing cell) activity, with net positive effects on bone mineral density over 12+ months of treatment.

Key Takeaway: GH secretagogues like sermorelin and ipamorelin stimulate your body's own GH production through natural pulsatile release, rather than injecting supraphysiological doses of exogenous GH. This preserves the feedback loop and avoids the dramatic IGF-1 spikes associated with direct GH injection — a meaningful safety distinction.

The GH-Longevity Paradox: The Most Important Section of This Article

Everything above describes why GH secretagogues are popular. This section explains why longevity scientists are concerned. The evidence on both sides is real, and the tension is unresolved.

The Longevity Case Against GH

The GH/IGF-1 signaling pathway is one of the most consistently identified pro-aging pathways across species. The evidence is extensive:

Laron syndrome. People with Laron syndrome have a genetic mutation in the GH receptor – their pituitary produces GH, but their cells cannot respond to it. IGF-1 levels are extremely low. They are short in stature but, remarkably, they are essentially immune to cancer and diabetes. Guevara-Aguirre et al. (2011, Science Translational Medicine, PMID 21325617) studied an Ecuadorian cohort of Laron individuals and found near-zero cancer incidence and dramatically reduced diabetes rates compared to their unaffected relatives.

GH receptor knockout mice. Ames dwarf mice and Snell dwarf mice – both of which have dramatically reduced GH/IGF-1 signaling – live 40-60% longer than normal mice. This is one of the largest and most reproducible lifespan extensions ever demonstrated in mammals (Brown-Borg et al., 1996, Nature).

IGF-1 and cancer. Higher circulating IGF-1 levels are consistently associated with increased cancer risk across multiple cancer types. IGF-1 is a potent cell proliferation and cell survival signal – exactly what cancer cells exploit for growth. Major epidemiological studies (Renehan et al., 2004, Lancet) show dose-dependent associations between IGF-1 levels and cancer incidence.

Centenarian IGF-1 levels. Multiple studies of centenarians (people who live past 100) have found that they tend to have lower IGF-1 levels than average. Their GH/IGF-1 axis appears to be naturally "dialed down" compared to the general population.

mTOR connection. IGF-1 activates the mTOR pathway (mechanistic target of rapamycin – the master growth-signaling cascade that controls cell growth, protein synthesis, and metabolism). mTOR inhibition, through rapamycin or caloric restriction, consistently extends lifespan across species. GH secretagogues, by increasing IGF-1, activate mTOR – the opposite of what longevity interventions typically aim to do. See mTOR and AMPK: The Master Switches of Aging for the full picture.

What Peter Attia Says

Peter Attia – the physician and longevity researcher who hosts The Drive podcast and authored Outlive – has been notably cautious about GH peptides. His position, stated across multiple podcast episodes: growth hormone is not an anti-aging molecule in healthy adults. Attia acknowledges the body composition benefits but argues that the long-term cancer risk from chronically elevated IGF-1 is a serious concern that the anti-aging industry under-communicates.

Attia's framework: the benefits of GH peptides (more muscle, less fat, better sleep, nicer skin) are real but cosmetic – they make you look and feel younger without necessarily making your biology younger. The underlying IGF-1 elevation may actually accelerate biological aging through increased cancer risk and mTOR activation.

What Andrew Huberman Says

Andrew Huberman – the Stanford neuroscientist who hosts the Huberman Lab podcast – has discussed GH primarily in the context of natural GH release. His emphasis has been on the substantial GH pulses produced by deliberate cold exposure, sauna use (see Sauna and Longevity: The Science of Heat Stress), high-intensity exercise, and deep sleep – arguing that optimizing these natural triggers may provide many of the benefits of GH peptides without the risks of chronic IGF-1 elevation.

The Nuance: Pulsatile vs. Chronic

Here is where the paradox gets more complicated – and where the GH peptide advocates have a legitimate point.

The longevity data against GH is primarily about chronic GH/IGF-1 elevation. Ames dwarf mice have low GH all the time. Laron individuals have non-functional GH receptors permanently. The cancer associations are with chronically elevated IGF-1 levels.

GH secretagogues – particularly the short-acting combinations like CJC-1295 (no DAC) + Ipamorelin – produce pulsatile GH elevation. The GH spike lasts 2-3 hours, IGF-1 rises transiently, and levels return to baseline. This is physiologically different from injecting exogenous GH (which produces sustained, supraphysiological levels) or having genetically elevated GH signaling (which is permanent).

The question: does pulsatile GH release carry the same longevity risks as chronic elevation? The honest answer is: we don't know. The longevity studies used genetic models (permanent GH reduction or elimination), not pulsatile supplementation models. The cancer epidemiology links fasting IGF-1 levels (a chronic measure) to risk. No study has specifically examined whether peptide-induced pulsatile GH release affects cancer risk or lifespan differently than chronic GH elevation.

This is the gap in the evidence that makes the GH peptide debate genuinely unresolvable with current data.

Key Takeaway: This is the central tension: GH decline with age causes sarcopenia, bone loss, and cognitive decline. But elevated GH/IGF-1 signaling is consistently associated with shortened lifespan across species. The Laron syndrome population (GH receptor deficiency) has near-zero cancer rates. Any GH optimization strategy must navigate this paradox carefully — restoring youthful function without chronic IGF-1 elevation.

Safety Concerns

Safety Note: GH-stimulating peptides raise IGF-1 levels, which may promote growth of existing cancers. Individuals with active cancer, a history of cancer, or a family history of cancer should avoid GH peptides. These compounds require physician oversight, regular IGF-1 monitoring, and metabolic panel tracking.

Established Side Effects of GH Elevation

• Insulin resistance – GH is counter-regulatory to insulin. Chronic GH elevation can impair glucose tolerance. This is measurable and can be monitored with fasting glucose, fasting insulin, and HbA1c testing.
• Fluid retention – edema, joint stiffness, and carpal tunnel syndrome are common with supraphysiological GH levels. Less common with pulsatile secretagogue use than with direct GH injection.
• Increased IGF-1 – the theoretical cancer risk concern. Monitoring IGF-1 levels during treatment is standard practice.

Theoretical Concerns

• Cancer promotion – IGF-1 is a growth factor. It does not cause cancer, but it may promote the growth of existing cancers (including microscopic tumors that are common and usually harmless in middle-aged and older adults). Anyone with active cancer or a history of cancer should approach GH peptides with extreme caution.
• Accelerated biological aging – if the longevity research is correct that GH/IGF-1 signaling is pro-aging, even pulsatile GH stimulation may be moving the aging trajectory in the wrong direction.
• Pituitary dependency – theoretical concern that chronic stimulation could desensitize pituitary somatotrophs, reducing natural GH production. This has not been demonstrated with secretagogue use at standard doses, but long-term data is limited.

Monitoring Recommendations

Anyone using GH secretagogues should monitor:

• IGF-1 levels – aim for upper-normal range, not supraphysiological. Levels above the age-adjusted reference range increase theoretical cancer risk.
• Fasting glucose and insulin – monitor for insulin resistance development
• HbA1c – longer-term glucose control marker
• Cancer screening – age-appropriate screening should be current and maintained

Who Might Benefit (and Who Should Be Cautious)

Potential benefit (with monitoring):

• Adults with documented, symptomatic GH decline (low IGF-1, poor body composition, impaired recovery, poor sleep quality)
• Post-surgical or post-injury recovery (short-term use)
• Athletes in high-training-volume phases (short-term use for recovery)

Proceed with caution:

• Anyone with a personal or strong family history of cancer
• Anyone with pre-diabetes or diabetes (GH worsens insulin resistance)
• Anyone taking mTOR-activating supplements or with elevated baseline IGF-1
• Anyone pursuing longevity optimization – the fundamental tension with the GH/IGF-1 pro-aging evidence should be honestly weighed

Alternative approaches to GH optimization:

• High-intensity exercise – triggers substantial GH pulses naturally
• Deep sleep optimization – the largest natural GH pulse occurs during slow-wave sleep
• Sauna – heat stress triggers significant GH release (see Sauna and Longevity)
• Intermittent fasting – fasting increases GH secretion while simultaneously lowering IGF-1 (a potentially more longevity-favorable GH pattern)

The Bottom Line

GH secretagogues work. They increase growth hormone release. They improve body composition, sleep, skin quality, and recovery. These are real, measurable effects that explain their popularity in anti-aging medicine.

The question is not whether they work – it is whether they are net positive for long-term health and longevity. And that question does not have a clear answer.

The evidence that GH/IGF-1 signaling is pro-aging is among the most robust and reproducible findings in all of longevity research. The evidence that pulsatile GH stimulation carries the same risks as chronic elevation is insufficient to draw conclusions either way. And the evidence that GH peptides extend healthy lifespan in any organism is nonexistent – no lifespan study has been conducted with any GH secretagogue.

If you choose to use GH peptides, do so with open eyes: the short-term benefits are real, the long-term longevity implications are uncertain, and the honest scientific assessment is that you may be trading cosmetic aging improvement for accelerated biological aging. Or you may not. The data to resolve this question does not yet exist.

The most defensible position in 2026 is the one that acknowledges the paradox rather than pretending it does not exist.

Related Reading

• Peptides and Longevity: The Complete Guide (2026)
• Exercise and Longevity: What Actually Works
• Sleep and Longevity: What Supplements Actually Help
• Sauna and Longevity: The Science of Heat Stress
• mTOR and AMPK: The Master Switches of Aging

References

1. Rudman, D., et al. (1990). "Effects of human growth hormone in men over 60 years old." New England Journal of Medicine, 323(1), 1-6. PMID 2355952.
2. Raun, K., et al. (1998). "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 139(5), 552-561.
3. Teichman, S.L., et al. (2006). "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
4. Walker, R.F. (2006). "Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging, 1(4), 307-318.
5. Vittone, J., et al. (1997). "Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men." Journals of Gerontology, 52A(1), M64-M73.
6. Anderson, N.B., et al. (2001). "Ipamorelin improves nitrogen balance in postoperative patients." Growth Hormone & IGF Research, 11(1), 45-51.
7. Guevara-Aguirre, J., et al. (2011). "Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans." Science Translational Medicine, 3(70), 70ra13. PMID 21325617.
8. Brown-Borg, H.M., et al. (1996). "Dwarf mice and the ageing process." Nature, 384, 33.
9. Renehan, A.G., et al. (2004). "Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk." Lancet, 363(9418), 1346-1353.
10. Bartke, A. (2011). "Single-gene mutations and healthy ageing in mammals." Philosophical Transactions of the Royal Society B, 366(1561), 28-34.
11. Laron, Z. (2004). "Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003." Journal of Clinical Endocrinology & Metabolism, 89(3), 1031-1044.

This article is for informational purposes only and does not constitute medical advice. GH secretagogues are not FDA-approved for anti-aging use in adults. Sermorelin is FDA-approved only for diagnostic testing and treatment of GH deficiency in children. Consult a licensed healthcare provider before using any peptide compound.